Supernus Pharmaceuticals | SUPN - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Abbott USD 10.46B 1.15B 2026-06
ANI Pharmaceuticals USD 597.21M 34.91M 2026-06
Aurora Cannabis CAD 48.04M 81.94M 2026-03
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Canopy Growth CAD 98.72M 11.51M 2026-03
Cara Therapeutics USD 7.05M 1.11M 2026-03
Corcept Therapeutics USD 214.85M 343K 2026-06
Eisai JPY 209.6B 6.14B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Novo Nordisk DKK 44.73B 7.52B 2026-06
Pacira USD 180.54M 7.79M 2026-06
Perrigo USD 290.5M 645.1M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Supernus Pharmaceuticals USD 1.03B 45.58M 2026-06
United Therapeutics USD 6.4B 499.2M 2026-06
Xeris Pharmaceuticals USD 75.21M 6.18M 2026-03